MidEuropa, a leading private equity investor with deep roots in Central Europe, announces that its portfolio company, Diagnostyka, a leading provider of medical diagnostic services in Poland, has debuted on the Warsaw Stock Exchange on Friday, February 7, 2025.
The market closing price on the first day of trading puts Diagnostyka s market capitalisation at over €1 billion. Diagnostyka thus ranks as the second-largest publicly listed healthcare services provider in Central Europe and among
The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform.
m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, research centers, and companies to develop scalable, personalized grafts for tissue repair.
– Prize money of one million euros higher than the prize money for the Nobel Prize for Medicine
– Award honors researchers worldwide who have done pioneering work in medicine, biotechnology, or related fields
The nomination period for the Broermann Medical Innovation Award has started. The prize, which will be awarded for the first time this year, is aimed at scientists worldwide who have carried out pioneering work in medicine, biotechnology, or related fields with their research.
The Autonomous Sperm Selection AI-based Robotic System is Poised to Transform the IVF Market
BAIBYS™ (https://www.baibys.com/), a pioneering Israeli startup in AI-powered micro-robotics for Artificial Reproductive Technology (ART), today announced it has received the CE mark for its innovative BAIBYS™ system (https://www.youtube.com/watch?v=Vaa_HlxuAm0). This milestone enables the company to commercialize its autonomous sperm selection technology across Europe, marking a significant
Back to media releases (https://norgine.com/media)
Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/)
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i
– Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases.
– The EC approval follows a positive opinion issued on 19 October 2024 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union (EU) Member States plus Iceland, Norway and Liechtenst
Pulsenmore (TASE: PULS), a pioneering provider of home-based ultrasound technology, has announced the renewal and expansion of its strategic partnership with Clalit Health Services, Israel s largest HMO. Over the next five years, Pulsenmore will supply 25,000 units of its advanced home ultrasound devices to support Clalit s commitment to accessible, high-quality prenatal care.
Under the new agreement, Pulsenmore s devices will enable pregnant women to conduct ultrasound scans at home, both asyn
Epitomee Medical Ltd. (TASE: EPIT) announces today that the company leadership intends to present Epitomee s Oral Delivery of Biologics Platform at the 14th Annual PODD Conference – Partnership Opportunities in Drug Delivery, taking place in Boston, MA, October 28-29, 2024.
Presentation Title: "Breakthrough Device for Oral Delivery of Biologics".
Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO").
Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with an undisputed track record of serving a loyal and broad global customer base. With the acquisition of Gentronix, Scantox s service platform expands sign
Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR clinical study at the HansonWade 4th Inner Ear Disorders Therapeutics Summit in Boston (MA) from August 20–22, and at the 36th World Congress of Audiology from September 19–22, 2024.
The PROHEAR study is a placebo-controlled Phase 2a study with split-body design investigating the otoprotective
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://www.so-co-it.com/wp-content/uploads/716035.jpg "Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma")
